Future Market Insights16h
Global Cellular Reprogramming Tools Market Poised for Substantial Growth, Projected to Reach USD 700 Million by 2033
The global cellular reprogramming tools market is on an impressive growth trajectory, with a projected valuation of USD 400 ...
Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue
Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
NEW YORK (Reuters) - Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene ...
Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
manilatimes5d
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
R&D Expenses: Research and development expenses for the third quarter of 2024 were $1.0 million, compared to $1.9 million for ...
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...
Ottumwa Courier5d
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent ...
Dr. Graff—a distinguished oncology expert with over 25 years in drug development who previously served as a consultant to Allarity—and Dr. Iglesias—a seasoned leader in oncology clinical trials and ...